Wilmar M. Wiersinga Antithyroid drugs (ATD) are nowadays the preferred treatment modality of Graves’ hyperthyroidism, but recurrent hyperthyroidism after a course of ATD is a major drawback. To predict recurrences from baseline data, a prospective study was done in 178 consecutive patients with first episode of Graves’ hyperthyroidism treated for one year with ATD (Vos […]